Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  May 12  EXTEND option available in structure searching
 NEWS  4  May 12  Polymer links for the POLYLINK command completed in REGISTRY
 NEWS  5  May 27  New UPM (Update Code Maximum) field for more efficient patent
                  SDIs in CAplus
 NEWS  6  May 27  CAplus super roles and document types searchable in REGISTRY
 NEWS  7  Jun 28  Additional enzyme-catalyzed reactions added to CASREACT
 NEWS  8  Jun 28  ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                  and WATER from CSA now available on STN(R)
 NEWS  9  Jul 12  BEILSTEIN enhanced with new display and select options,
                  resulting in a closer connection to BABS
 NEWS 10  Jul 30  BEILSTEIN on STN workshop to be held August 24 in conjunction
                  with the 228th ACS National Meeting
 NEWS 11  AUG 02  IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                  fields
 NEWS 12  AUG 02  CAplus and CA patent records enhanced with European and Japan
                  Patent Office Classifications
 NEWS 13  AUG 02  STN User Update to be held August 22 in conjunction with the
                  228th ACS National Meeting
 NEWS 14  AUG 02  The Analysis Edition of STN Express with Discover!
                  (Version 7.01 for Windows) now available
 NEWS 15  AUG 04  Pricing for the Save Answers for SciFinder Wizard within
                  STN Express with Discover! will change September 1, 2004
 NEWS 16  AUG 27  BIOCOMMERCE: Changes and enhancements to content coverage
 NEWS 17  AUG 27  BIOTECHABS/BIOTECHDS: Two new display fields added for legal
                  status data from INPADOC
 NEWS 18  SEP 01  INPADOC: New family current-awareness alert (SDI) available
 NEWS 19  SEP 01  New pricing for the Save Answers for SciFinder Wizard within
                  STN Express with Discover!
 NEWS 20  SEP 01  New display format, HITSTR, available in WPIDS/WPINDEX/WPIX

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004

=> file medline, uspatful, dgene, embase, wpids, fsta,
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 17:33:04 ON 09 SEP 2004

FILE 'USPATFULL' ENTERED AT 17:33:04 ON 09 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:33:04 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 17:33:04 ON 09 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:33:04 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 17:33:04 ON 09 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s hypergylcemia or hypoglycemia
L1 47616 HYPERGYLCEMIA OR HYPOGLYCEMIA

=> s l1 and non-peptidyl compound
L2 17 L1 AND NON-PEPTIDYL COMPOUND

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 17 USPATFULL on STN
TI Method of regulating glucose metabolism, and reagents related thereto
AB The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.

ACCESSION NUMBER: 2004:227921 USPATFULL
TITLE: Method of regulating glucose metabolism, and reagents related thereto
INVENTOR(S): Bachovchin, William W., Melrose, MA, UNITED STATES
Plaut, Andrew G., Lexington, MA, UNITED STATES
Drucker, Daniel, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176307	A1	20040909
APPLICATION INFO.:	US 2004-794316	A1	20040304 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-190267, filed on 3 Jul 2002, PENDING Continuation of Ser. No. US 2000-628225, filed on 28 Jul 2000, PENDING Continuation of Ser. No. WO 1999-US2294, filed on 2 Feb 1999, PENDING

NUMBER	DATE

PRIORITY INFORMATION: US 1998-73409P 19980202 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2431

L2 ANSWER 2 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:85155 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6716586	B1	20040406
APPLICATION INFO.:	US 2000-724065		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:78964 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6713451	B1	20040330
APPLICATION INFO.:	US 2000-724062		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 17 USPATFULL on STN
TI DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof
AB This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:72563 USPATFULL
TITLE: DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof
INVENTOR(S): Gerald, Christophe P. G., Ridgewood, NJ, United States
Jones, Kenneth A., Bergenfield, NJ, United States
Bonini, James A., Oakland, NJ, United States
Borowsky, Beth E., Montclair, NJ, United States
Craig, Douglas A., Emerson, NJ, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6709831	B1	20040323
APPLICATION INFO.:	US 1999-405558		19990924 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-255368, filed on 22 Feb 1999, now patented, Pat. No. US 6262246
Continuation-in-part of Ser. No. US 1998-161113, filed on 25 Sep 1998, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Eyler, Yvonne
ASSISTANT EXAMINER: Murphy, Joseph F.
LEGAL REPRESENTATIVE: White, John P., Cooper & Dunham LLP
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 39 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 5391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 17 USPATFULL on STN

TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:41453 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, NEW ZEALAND Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693079	B1	20040217
APPLICATION INFO.:	US 2000-724157		20001128 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David S.
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT:	5389

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:41452 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, NEW ZEALAND Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693078	B1	20040217
APPLICATION INFO.:	US 2000-724095		20001128 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David S.
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 65 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:34008 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689751	B1	20040210
APPLICATION INFO.:	US 2000-723912		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:21596 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Devonport, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683053	B1	20040127
APPLICATION INFO.:	US 2000-723913		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.

LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Dreger, Esq., Ginger R., Heller Ehrman White & McAuliffe LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5367
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:15030 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6680298	B1	20040120
APPLICATION INFO.:	US 2000-724114		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 49 Drawing Page(s)
LINE COUNT: 5376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:9592 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677305	B1	20040113
APPLICATION INFO.:	US 2000-723873		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852,

filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:296863 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6645775	B1	20031111
APPLICATION INFO.:	US 2000-723931		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 67 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:279179 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6635619	B1	20031021
APPLICATION INFO.:	US 2000-724127		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller, Ehrman, White & McAuliffe, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 49 Drawing Page(s)
LINE COUNT: 5375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:273418 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6632794	B1	20031014
APPLICATION INFO.:	US 2000-723547		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:246897 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND

Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C.A.F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620789	B1	20030916
APPLICATION INFO.:	US 2000-723901		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 17 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:222090 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6608031	B1	20030819
APPLICATION INFO.:	US 2000-723890		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 17 USPATFULL on STN
TI Method of regulating glucose metabolism, and reagents related thereto
AB The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and

LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:220218 USPATFULL
TITLE:	Method of regulating glucose metabolism, and reagents related thereto
INVENTOR(S):	Bachovchin, William W., Melrose, MA, UNITED STATES Plaut, Andrew G., Lexington, MA, UNITED STATES Drucker, Daniel, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153509	A1	20030814
APPLICATION INFO.:	US 2002-190267	A1	20020703 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-628225, filed on 28 Jul 2000, PENDING Continuation of Ser. No. WO 1999-US2294, filed on 2 Feb 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-73409P	19980202 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Matthew P. Vincent, Patent Group, Foley, Hoag & Eliot LLP, One Post Office Square, Boston, MA, 02109
NUMBER OF CLAIMS:	37
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	2430

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 17 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:97888 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, New Zealand Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, United Kingdom
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David
LEGAL REPRESENTATIVE:	Hasak, Janet E.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT:	4925

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 17:33:04
     ON 09 SEP 2004
L1         47616 S HYPERGYLCEMIA OR HYPOGLYCEMIA
L2            17 S L1 AND NON-PEPTIDYL COMPOUND

=> s l1 and treatment
L3         13598 L1 AND TREATMENT

=> s l3 and insulin agonist
L4            10 L3 AND INSULIN AGONIST

=> s insulin antagonist
L5           135 INSULIN ANTAGONIST

=> s l5 and l4
L6             1 L5 AND L4

=> d l6 ti abs ibib tot

L6   ANSWER 1 OF 1  USPATFULL on STN
TI     Insulin-associated peptides with effects on cerebral health
AB     The present invention provides compositions and methods for ameliorating
       neurological, attention, or memory disorders and improving learning and
       cognition through the delivery of insulin A-chain and analogs thereof to
       a subject. Insulin A-chain, peptides comprising the 21 amino acid
       sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs
       thereof are disclosed to modulate neurological activity when
       administered to a subject. The methods of the invention can be used to
       prevent or treat neurological disorders as well as improve memory
       retention and acquisition. The invention includes pharmaceutical
       compositions comprising a therapeutically or prophylactically effective
       amount of insulin A-chain peptide or a functional analogs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2004:19356  USPATFULL
TITLE:                    Insulin-associated peptides with effects on cerebral
                          health
INVENTOR(S):              During, Matthew J., Philadelphia, PA, UNITED STATES
                          Haile, Colin N., Katy, TX, UNITED STATES

                               NUMBER        KIND    DATE
                          --------------- ------ --------
PATENT INFORMATION:       US 2004014660      A1   20040122
APPLICATION INFO.:        US 2003-430545     A1   20030506  (10)

                                 NUMBER        DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2002-378318P    20020506 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST,
                          155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604
NUMBER OF CLAIMS:         13
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       12 Drawing Page(s)
LINE COUNT:               2477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
=> d his

     (FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 17:33:04
     ON 09 SEP 2004
L1         47616 S HYPERGYLCEMIA OR HYPOGLYCEMIA
L2            17 S L1 AND NON-PEPTIDYL COMPOUND
L3         13598 S L1 AND TREATMENT
L4            10 S L3 AND INSULIN AGONIST
L5           135 S INSULIN ANTAGONIST
L6             1 S L5 AND L4

=> s l5 and l1
L7            32 L5 AND L1

=> d l4 ti abs ibib tot

L4   ANSWER 1 OF 10  USPATFULL on STN
TI     Methods of reducing hypoglycemic episodes in the treatment of
       diabetes mellitus
AB     The present invention provides compositions and methods for reducing
       hypoglycemic episodes experienced by a subject in need of
       treatment for diabetes mellitus, said method comprising orally
       administering an amount of an insulin polypeptide-oligomer conjugate to
       the subject, wherein: i) the amount of the insulin polypeptide-oligomer
       conjugate reduces the number and/or severity of hypoglycemic episodes
       experienced by the subject during a given time period when compared with
       the number and/or severity of hypoglycemic episodes that would have been
       experienced during a similar time period by the subject or by subjects
       in a control group parenterally administered insulin or an insulin
       analog in an amount that provides a substantially equivalent level of
       glycemic control; and ii) the oligomer of the insulin
       polypeptide-oligomer conjugate comprises a hydrophilic moiety and a
       lipophilic moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2004:51436  USPATFULL
TITLE:                   Methods of reducing hypoglycemic episodes in the
                         treatment of diabetes mellitus
INVENTOR(S):             Still, James Gordon, Raleigh, NC, UNITED STATES
                         Kosutic, Gordana, Raleigh, NC, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004038867      A1   20040226
APPLICATION INFO.:       US 2003-461199     A1   20030613  (10)

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2002-388988P    20020613 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH,
                         NC, 27627
NUMBER OF CLAIMS:        22
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      2 Drawing Page(s)
LINE COUNT:              2168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 2 OF 10  USPATFULL on STN
TI     Insulin-associated peptides with effects on cerebral health
```

AB The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:19356 USPATFULL			
TITLE:	Insulin-associated peptides with effects on cerebral health			
INVENTOR(S):	During, Matthew J., Philadelphia, PA, UNITED STATES Haile, Colin N., Katy, TX, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014660	A1	20040122	
APPLICATION INFO.:	US 2003-430545	A1	20030506	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2002-378318P		20020506	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604			
NUMBER OF CLAIMS:	13			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	12 Drawing Page(s)			
LINE COUNT:	2477			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN

TI Single-chain insulin analog and a polynucleotide sequence encoding the analog

AB The subject matter of the invention is directed to a single-chain insulin analog that is used to treat diabetes by gene therapy methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:268156 USPATFULL			
TITLE:	Single-chain insulin analog and a polynucleotide sequence encoding the analog			
INVENTOR(S):	Lee, Hyun Chul, Seodaemungu Hongeundong 268, Dongdo-academyhouse A-402, Seoul, KOREA, REPUBLIC OF Kim, Su-Jin, Dukyanggu Haengsindong 938 Haibit 1819-1304, Goyangsi, KOREA, REPUBLIC OF Kim, Kyung Sup, Yongdeungpogu Yeoyeedodong Samik, Apt. B-202, Seoul, KOREA, REPUBLIC OF Shin, Hang-Cheol, Seochogu Wonjidong 401-37, Seoul, KOREA, REPUBLIC OF Yoon, Ji-Won, 206 Edgeview Drive, N.W., Calgary, Alberta, CANADA T3A 4X5			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6630348	B1	20031007	
APPLICATION INFO.:	US 2000-706690		20001107	(9)
	NUMBER		DATE	

PRIORITY INFORMATION:	KR 2000-58003	20001002
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kemmerer, Elizabeth	
ASSISTANT EXAMINER:	Bunner, Bridget E.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	1243	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN

TI Methods of treating diabetes mellitus

AB Methods of treating diabetes mellitus in a patient in need of such **treatment** include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may "activate" the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:71941 USPATFULL		
TITLE:	Methods of treating diabetes mellitus		
INVENTOR(S):	Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES Price, Christopher H., Chapel Hill, NC, UNITED STATES Still, James Gordon, Raleigh, NC, UNITED STATES Filbey, Jennifer Ann, Raleigh, NC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050228	A1	20030313
APPLICATION INFO.:	US 2002-75097	A1	20020213 (10)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2001-269198P		20010215 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627		
NUMBER OF CLAIMS:	230		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	3140		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN

TI **Treatment** of acute and chronic liver disease

AB The present invention relates to IGF-1 **treatment** of an individual, such as e.g. a human being, suffering from an acute or chronic liver disease including hepatic cirrhosis. Acute and chronic liver disease according to the invention are characterized by low circulating IGF-1 and IGFBP3 levels. According to one preferred embodiment of the present invention, IGF-1 is administrered to a human being subcutaneously, preferably in the thigh or the abdominal skin, and preferably in two daily doses of about 50 microgram/kg twice a day. The present invention demonstrates that this dosis regime is able to restore normal IGF-1 levels in patients with liver cirrhosis, and the dose is well-tolerated by the patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:48572 USPATFULL

TITLE: **Treatment** of acute and chronic liver disease
INVENTOR(S): Grofte, Thorbjorn, Viby J., DENMARK
Vilstrup, Hendrik, Risskov, DENMARK
PATENT ASSIGNEE(S): Aarhus Amt., Hojbjerg, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002028764	A1	20020307
APPLICATION INFO.:	US 2001-928832	A1	20010814 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-1317	20000904
	US 2000-237715P	20001005 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC, 20001
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3074
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN
TI Amylin activity assays
AB Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:43755 USPATFULL
TITLE: Amylin activity assays
INVENTOR(S): Young, Andrew A., San Diego, CA, United States
Cooper, Garth J. S., Solana Beach, CA, United States
Rink, Timothy J., La Jolla, CA, United States
PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6048514		20000411
APPLICATION INFO.:	US 1995-422747		19950414 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-88629, filed on 6 Jul 1993, now abandoned which is a continuation of Ser. No. US 1991-666527, filed on 8 Mar 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-640478, filed on 10 Jan 1991, now patented, Pat. No. US 5234906
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPATFULL on STN
TI Insulin receptor
AB Insulin receptor is purified in accordance with this invention to a level sufficient to enable amino acid sequencing thereof. DNA encoding insulin receptor is provided, as well as methods for synthesizing insulin receptor or its mutant in heterologous host cells transformed with vectors containing such DNA. Knowledge of the amino acid sequence for insulin receptor enables the preparation of novel immunogenic conjugates and antibodies raised against such conjugates. Novel therapeutically useful forms of the insulin receptor and anti-receptor antibodies are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	88:48719 USPATFULL		
TITLE:	Insulin receptor		
INVENTOR(S):	Bell, John R., San Francisco, CA, United States Ramachandran, Janakiraman, Palo Alto, CA, United States Ullrich, Axel, San Francisco, CA, United States		
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4761371		19880802
APPLICATION INFO.:	US 1985-700776		19850212 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wiseman, Thomas G.		
ASSISTANT EXAMINER:	Seidman, Stephanie		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1144		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Improving insulin therapy: Achievements and challenges.
AB Microvascular complications of diabetes can be forestalled by effective glycemic control. However, the inherent limitations of standard subcutaneous insulins reduce their ability to control glycemia without risk of significant **hypoglycemia** and hyperinsulinemia. **Hypoglycemia** is unacceptable for most patients and may be dangerous. Hyperinsulinemia is undesirable because it causes weight gain and it has a putative association with atherosclerosis. This paper summarizes the major historical improvements in insulin therapy, and calls attention to the fact that none of the presently available commercial preparations in any combination is capable of simulating the profile of normal insulin secretion - the latter being regarded as the most effective means of normalizing glycemia. For this reason, a variety of new approaches to simulating the pharmacokinetics or glucodynamics of insulin secretion are under investigation. Fast-acting insulin analogues suitable for subcutaneous injection have been developed and appear to mimic the physiological insulin response more closely than standard insulins. Less progress has been made with basal insulins. Intravenous insulin has pharmacodynamic advantages but practical disadvantages of administration. Nasal insulin would be an attractive **treatment** modality only if its bioavailability could be significantly increased and its safety assured. Other interventions which improve glucose metabolism without necessarily simulating normal insulin secretion are under investigation. These include biosynthetic human C-peptide, insulin-like growth factor-1 and glucagon-like peptide 1 (7-36 amide).

ACCESSION NUMBER:	94381559 EMBASE
DOCUMENT NUMBER:	1994381559

TITLE: Improving insulin therapy: Achievements and challenges.
AUTHOR: Galloway J.A.; Chance R.E.
CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corporate Center,Indianapolis, IN 46285, United States
SOURCE: Hormone and Metabolic Research, (1994) 26/12 (591-598).
ISSN: 0018-5043 CODEN: HMMRA2
COUNTRY: Germany
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L4 ANSWER 9 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Composition useful for the **treatment** of diabetes in a human or other mammal or for preventing **hypoglycemia** in diabetes patient treated with insulin and who is not suffering from hypoglycemic symptoms comprises insulin and glucagon.
AN 2004-543797 [52] WPIDS
AB WO2004060387 A UPAB: 20040813
NOVELTY - A pharmaceutical composition comprises insulin and glucagon for controlling diabetes and preventing **hypoglycemia** in a human or other mammal.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an infusion pump containing both insulin and glucagon.
ACTIVITY - Antidiabetic.
A mixture of insulin and glucagon (1.5 %) (optionally modified release glucagon) was administered to the patient suffering from diabetes (35 years) and using insulin therapy from the time of diagnosis using pump (for both basal and prandial insulin). The results showed protection form **hypoglycemia** over the period of susceptibility as required.
MECHANISM OF ACTION - **Insulin agonist**; Glucagon agonist.
USE - In infusion pump; for the **treatment** of diabetes in a human or other mammal; for preventing **hypoglycemia** in diabetes patient treated with insulin and who is not suffering from hypoglycemic symptoms (all claimed).
ADVANTAGE - The composition controls and treats diabetes while reducing or eliminating the risk of insulin-induced **hypoglycemia** . The composition maintains blood glucose levels that is, neither hyperglycemic nor hypoglycemic; prevents or reduces the frequency and severity of **hypoglycemia** in insulin-treated diabetic patients (both type 1 and type 2); can used to replenish or restore the abnormally low glucagons responses often coincident with insulin administration, thus preventing **hypoglycemia**. The composition, containing the insulin and glucagon are combined in a molar ratio that optimize glycemic management and attenuate the incidence of or prevent **hypoglycemia** .
Dwg.0/7
ACCESSION NUMBER: 2004-543797 [52] WPIDS
DOC. NO. CPI: C2004-199555
TITLE: Composition useful for the **treatment** of diabetes in a human or other mammal or for preventing **hypoglycemia** in diabetes patient treated with insulin and who is not suffering from hypoglycemic symptoms comprises insulin and glucagon.
DERWENT CLASS: B04
INVENTOR(S): GREEN, D T; HENRY, R R
PATENT ASSIGNEE(S): (DIOB-N) DIOBEX INC
COUNTRY COUNT: 107
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 2004060387 A1 20040722 (200452)* EN 55
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM
PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US
UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004060387	A1	WO 2003-US41103	20031223

PRIORITY APPLN. INFO: US 2003-470346P 20030513; US
2002-436735P 20021227; US
2003-454972P 20030314

L4 ANSWER 10 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Composition for **treatment** of diabetes with reduced side effects comprises an insulin sensitizer in combination with an anorectic.
AN 2000-147239 [13] WPIDS
AB WO 200000195 A UPAB: 20000313
NOVELTY - A pharmaceutical composition comprises an insulin sensitizer in combination with an anorectic.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:
(1) a method for reducing the side effects of an insulin sensitizer and/or an anorectic administered to a diabetic comprising administering an effect amount of them;
(2) a method for preventing or treating diabetes and impaired glucose tolerance in a mammal by administrating to the mammal the sensitizer in combination with an anorectic.
ACTIVITY - Antidiabetic; Anorectic.
The effects of concomitant administration of pioglitazone hydrochloride and mazindol in non-insulin-dependent diabetic mellitus (NIDDM) patients were studied. When pioglitazone hydrochloride (45mg/day p.o.) was concomitantly administered to an NIDDM patient under **treatment** with mazindol (1.0mg/day p.o.) over the period of 8 weeks, fasting blood sugar decreased by 70 mg/dl, HbA1c decreased by 2% and body weight decreased by 1.0 kg.
MECHANISM OF ACTION - **Insulin-Agonist.**
USE - The composition is useful for preventing and treating diabetes, diabetic complications and for treating impaired glucose tolerance. The composition possesses an increased blood sugar lowering action, blood lipid lowering action or blood insulin lowering action as compared with administration of an insulin sensitizer or an anorectic alone.
ADVANTAGE - Use of the present composition in combination with insulin enables reduction of the amount of insulin used when compared with the amount used at the time of administration of insulin alone. Therefore, risk of blood vessel complication and **hypoglycemia** induction is low.
Dwg.0/0

ACCESSION NUMBER: 2000-147239 [13] WPIDS
DOC. NO. CPI: C2000-046089
TITLE: Composition for **treatment** of diabetes with reduced side effects comprises an insulin sensitizer in combination with an anorectic.
DERWENT CLASS: B03
INVENTOR(S): ODAKA, H; YAMANE, M
PATENT ASSIGNEE(S): (TAKE) TAKEDA CHEM IND LTD; (ODAK-I) ODAKA H; (YAMA-I) YAMANE M

COUNTRY COUNT: 86
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000000195	A1	20000106	(200013)*	EN	43
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU ZA					
JP 2000080047	A	20000321	(200025)		14
AU 9942914	A	20000117	(200026)		
BR 9911656	A	20010320	(200123)		
NO 2000006630	A	20010226	(200123)		
EP 1093370	A1	20010425	(200124)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
CN 1305376	A	20010725	(200164)		
KR 2001043455	A	20010525	(200168)		
US 6329403	B1	20011211	(200204)		
ZA 2000006262	A	20020130	(200217)		54
MX 2000010582	A1	20010501	(200227)		
US 2002086885	A1	20020704	(200247)		
AU 754740	B	20021121	(200305)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2000000195	A1		WO 1999-JP3496	19990629
JP 2000080047	A		JP 1999-183299	19990629
AU 9942914	A		AU 1999-42914	19990629
BR 9911656	A		BR 1999-11656	19990629
			WO 1999-JP3496	19990629
NO 2000006630	A		WO 1999-JP3496	19990629
			NO 2000-6630	20001222
EP 1093370	A1		EP 1999-957622	19990629
			WO 1999-JP3496	19990629
CN 1305376	A		CN 1999-807133	19990629
KR 2001043455	A		KR 2000-712502	20001108
US 6329403	B1		WO 1999-JP3496	19990629
			US 1999-380059	19990825
ZA 2000006262	A		ZA 2000-6262	20001102
MX 2000010582	A1		MX 2000-10582	20001027
US 2002086885	A1	Div ex	WO 1999-JP3496	19990629
		Div ex	US 1999-380059	19990825
			US 2001-36208	20011229
AU 754740	B		AU 1999-42914	19990629

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9942914	A	Based on	WO 2000000195
BR 9911656	A	Based on	WO 2000000195
EP 1093370	A1	Based on	WO 2000000195
US 6329403	B1	Based on	WO 2000000195
AU 754740	B	Previous Publ.	AU 9942914
		Based on	WO 2000000195

PRIORITY APPLN. INFO: JP 1998-183700 19980630

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 32 MEDLINE on STN
TI Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.
AB Prohormone convertase 2 (PC2) plays an essential role in the processing of proglucagon to mature active glucagon in pancreatic alpha-cells (J Biol Chem 276:27197-27202, 2001). Mice lacking PC2 demonstrate multiple defects, including chronic mild **hypoglycemia** and dramatic hyperplasia of the pancreatic alpha-cells. To define the contribution of mature glucagon deficiency to the **hypoglycemia** and alpha-cell hyperplasia, we have attempted to correct the defects by delivery of exogenous glucagon by micro-osmotic pumps. Intraperitoneal delivery of 0.5 microg glucagon/h in PC2(-/-) mice resulted in the normalization of blood glucose concentrations. Islet remodeling through the loss of hyperplastic alpha-cells was evident by day 11 after pump implantation; by 25 days postimplantation, PC2(-/-) islets were indistinguishable from wild-type islets. These rapid changes were brought about by induction of apoptosis in the alpha-cell population. Morphological normalization of islets was also accompanied by marked downregulation of endogenous preproglucagon gene expression, but with little or no change in the level of preproinsulin gene expression. Exogenous glucagon delivery also normalized hepatic expression of the gluconeogenic enzyme PEPCK. These results demonstrate that the lack of mature glucagon in PC2(-/-) mice is responsible for the aberrant blood glucose levels, islet morphology, and gene expression, and they confirm the role of glucagon as a tonic **insulin antagonist** in regulating glycemia.
ACCESSION NUMBER: 2002132506 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11812747
TITLE: Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.
AUTHOR: Webb Gene C; Akbar Murtaza S; Zhao Chongjian; Swift Hewson H; Steiner Donald F
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA.
CONTRACT NUMBER: DK13914 (NIDDK)
DK2059 (NIDDK)
SOURCE: Diabetes, (2002 Feb) 51 (2) 398-405.
Journal code: 0372763. ISSN: 0012-1797.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200203
ENTRY DATE: Entered STN: 20020301
Last Updated on STN: 20021026
Entered Medline: 20020315

L7 ANSWER 2 OF 32 MEDLINE on STN
TI Insulin antagonism: a novel role for human serum transferrin.
AB We have purified alpha2-glycoprotein (alpha2-GP), an **insulin antagonist** from human plasma which is induced by growth hormone (GH), and shown that pure alpha2-GP is a potent antagonist of severe insulin-induced **hypoglycemia**, producing acute hyperglycemia in intact rats and ketonuria in diabetic rats. The N-terminal amino acid sequence of alpha2-GP and the reactivity of alpha2-GP with an antitransferrin monoclonal antibody show that alpha2-GP is identical to human serum transferrin. Furthermore, pure human serum transferrin and non-glycosylated recombinant human transferrin reproduce the **insulin antagonist** effects of alpha2-GP in rats, whereas ovotransferrin shows no such effect. The neutralization of the insulin antagonism of human serum transferrin by an anti-transferrin monoclonal antibody shows that transferrin has a new function as a potent **insulin antagonist**. This novel role for human serum

transferrin in the regulation of glucose metabolism provides a reasonable mechanism for the diabetogenic effect of GH, and has important implications for the etiology and progression of diabetes.

ACCESSION NUMBER: 1998226502 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9566850
TITLE: Insulin antagonism: a novel role for human serum transferrin.
AUTHOR: Vargas L; Kawada M E; Bazaes S; Karplus P A; Faerman C H
CORPORATE SOURCE: Department of Cell and Molecular Biology, Pontifical Catholic University of Chile, Santiago.
CONTRACT NUMBER: 1 P01 GM4887 (NIGMS)
SOURCE: Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et metabolisme, (1998 Mar) 30 (3) 113-7.
Journal code: 0177722. ISSN: 0018-5043.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199806
ENTRY DATE: Entered STN: 19980618
Last Updated on STN: 19980618
Entered Medline: 19980608

L7 ANSWER 3 OF 32 MEDLINE on STN
TI Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.
AB With isoelectric focusing, we examined heterogeneity of autoantibodies to insulin receptors in serums of two patients with insulin-resistant diabetes and one patient with **hypoglycemia**. Immunoglobulins were prepared by ammonium sulfate precipitation and ion-exchange chromatography with DEAE-Sepharose and subjected to isoelectric focusing for separation into 30 fractions. The fractions were tested for their ability to inhibit 125I-labeled insulin binding to human placental membranes, immunoprecipitate solubilized insulin receptor cross-linked with 125I-insulin, and mimic or inhibit the action of insulin in rat adipocytes. The results varied among the three patients. In the first patient, inhibition of 125I-insulin-binding activity (IBA) and insulin-receptor-precipitating activity (IPA) were distributed almost identically, but the distribution of insulinlike bioactivity (ILBA) was somewhat different. In the second patient, some fractions exhibited potent IBA without IPA, and these fractions inhibited the action of insulin in rat adipocytes. In the third patient, all of the isoelectric fractions showed IBA without IPA and were insulin antagonists. These observations indicate that some patients have antibodies with pure **insulin-antagonist** properties and provide further evidence that autoantibodies to insulin receptors are polyclonal and recognize different antigenic sites on insulin-receptor molecules. The findings also suggest that the ability of antibodies to elicit ILBA is linked to the ability to immunoprecipitate 125I-insulin-cross-linked and solubilized receptors, whereas antibodies that only inhibit insulin binding behave as insulin antagonists.

ACCESSION NUMBER: 89357274 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2767337
TITLE: Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.
AUTHOR: Tsushima T; Omori Y; Murakami H; Hirata Y; Shizume K
CORPORATE SOURCE: Second Department of Medicine, Tokyo Women's Medical College, Japan.
SOURCE: Diabetes, (1989 Sep) 38 (9) 1090-6.
Journal code: 0372763. ISSN: 0012-1797.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 198910
ENTRY DATE: Entered STN: 19900309
Last Updated on STN: 20000303
Entered Medline: 19891003

L7 ANSWER 4 OF 32 MEDLINE on STN
TI Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.
AB Continuous, low dose, insulin infusion in conscious dogs produced moderate **hypoglycemia** but only a transient fall in glucose production that rose towards preinfusion levels 20 to 30 min before any detectable increase in plasma counterregulatory hormones. Addition of epinephrine or glucagon to the insulin infusion prevented the fall in glucose production throughout the experiment but only partially diminished the hypoglycemic response. When **hypoglycemia** was prevented by a variable glucose infusion, neither epinephrine nor glucagon was able to counteract the suppressive effect of insulin on glucose output. These findings suggest that a fall in blood glucose per se may reverse insulin-induced inhibition of glucose production independent of a rise in counterregulatory hormones and that the **insulin antagonist** effect of counter-regulatory hormones is modulated, at least in part, by blood glucose concentration.
ACCESSION NUMBER: 79192270 MEDLINE
DOCUMENT NUMBER: PubMed ID: 446911
TITLE: Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.
AUTHOR: Sacca L; Cryer P E; Sherwin R S
SOURCE: Diabetes, (1979 Jun) 28 (6) 533-6.
Journal code: 0372763. ISSN: 0012-1797.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 197908
ENTRY DATE: Entered STN: 19900315
Last Updated on STN: 19900315
Entered Medline: 19790816

L7 ANSWER 5 OF 32 MEDLINE on STN
TI Insulin therapy and behaviors of **insulin antagonist** hormones, with special reference to the reactions of growth hormone and cortisol during the hypoglycemic stage in juvenile diabetes.
ACCESSION NUMBER: 79064260 MEDLINE
DOCUMENT NUMBER: PubMed ID: 719944
TITLE: Insulin therapy and behaviors of **insulin antagonist** hormones, with special reference to the reactions of growth hormone and cortisol during the hypoglycemic stage in juvenile diabetes.
AUTHOR: Egi S
SOURCE: Horumon to rinsho. Clinical endocrinology, (1978 Sep) 26 (9) 947-51.
Journal code: 0420561. ISSN: 0045-7167.
PUB. COUNTRY: Japan
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Japanese
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197902
ENTRY DATE: Entered STN: 19900314
Last Updated on STN: 19900314
Entered Medline: 19790223

L7 ANSWER 6 OF 32 MEDLINE on STN
TI Chlorpropamide-induced **hypoglycemia**: successful treatment with diazoxide.
AB A healthy adolescent boy was treated on two occasions for an overdose of chlorpropamide (Diabinese). Glucose therapy alone was not sufficient to control the **hypoglycemia**, but the administration of glucose plus diazoxide raised the blood sugar to supranormal levels. A bolus of intravenous glucagon briefly raised the blood sugar level to within normal limits, increased the blood ketones but also augmented insulin secretion. An overdose of sulfonylurea may cause prolonged and fatal **hypoglycemia**. Rational therapy, both in diabetic and normal persons, is glucose plus an "**insulin antagonist**." The administration of diazoxide was effective in our patient, substantially reducing the plasma insulin level; this agent may be the "**insulin -antagonist**" of choice for use in sulfonylurea-induced **hypoglycemia**.

ACCESSION NUMBER: 78058323 MEDLINE
DOCUMENT NUMBER: PubMed ID: 930951
TITLE: Chlorpropamide-induced **hypoglycemia**: successful treatment with diazoxide.
AUTHOR: Johnson S F; Schade D S; Peake G T
SOURCE: American journal of medicine, (1977 Nov) 63 (5) 799-804. Journal code: 0267200. ISSN: 0002-9343.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS) Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 197801
ENTRY DATE: Entered STN: 19900314 Last Updated on STN: 19900314 Entered Medline: 19780127

L7 ANSWER 7 OF 32 MEDLINE on STN
TI The relative roles of calcium, phosphorus, and parathyroid hormone in glucose- and tolbutamide-mediated insulin release.
AB The relative contributions of Ca++, phosphorus, and parathyroid hormone (PTH) on insulin secretion were evaluated in three groups of dogs. Dogs were studied with glucose infusions (group I) or standard intravenous glucose tolerance tests (IVGTT) (group II) before and after the development of diet-induced hypophosphatemia. Mean serum phosphorus levels for both groups fell from 4.1 to 1.1 mg/100 ml. Animals in group I demonstrated a fall in glucose disappearance rates (Kg) from 5.3+/-0.6% min to 3.5+/-0.5% after induction of hypophosphatemia (P less than 0.001). Mean insulin response was significantly greater in the hypophosphatemic animals than in controls in this group. In group II animals, mean insulin areas obtained during the IVGTT increased from 1,426+/-223 to 2,561+/-141 muU/ml/60 min after induction of hypophosphatemia, and were unaffected by Ca++ or PTH administration. Ca++ administration, but not hypophosphatemia or PTH infusion, increased significantly the mean insulin response to tolbutamide. Secondary hyperparathyroidism was induced by dietary manipulation in four dogs (group III). Mean PTH values increased from 71.4+/-2.1 to 3,012+/-372 pg/ml (P less than 0.001). Mean insulin response to an IVGTT was similar to group III animals, but increased from 1,352+/-128 to 1,894+/-360 muU/ml/60 min after the excessive dietary phosphorus was reduced for 3 mo, and plasma phosphorus fell from 3.2+/-0.1 to 2.8+/-0.3 mg/100 ml. PTH values decreased to 647+/-53 pg/ml. The insulin response to tolbutamide was comparable to that in group II animals, but increased significantly after calcium administration. Immunoreactive insulin disappearance rates were unaffected by hypophosphatemia or diet-induced secondary hyperparathyroidism. These data demonstrate that hypophosphatemia is associated with an augmented glucose-stimulated insulin release, without any effect on tolbutamide-stimulated insulin release. Hypercalcemia produces an

augmented tolbutamide-stimulated insulin release with no apparent effect on glucose-stimulated insulin release. Finally, PTH does not appear to be an **insulin antagonist** and has no apparent effect on either glucose- or tolbutamide-stimulated insulin release in animals with dietary-induced secondary hyperparathyroidism.

ACCESSION NUMBER: 76260562 MEDLINE
DOCUMENT NUMBER: PubMed ID: 956371
TITLE: The relative roles of calcium, phosphorus, and parathyroid hormone in glucose- and tolbutamide-mediated insulin release.
AUTHOR: Harter H R; Santiago J V; Rutherford W E; Slatopolsky E; Klahr S
SOURCE: Journal of clinical investigation, (1976 Aug) 58 (2) 359-67.
Journal code: 7802877. ISSN: 0021-9738.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 197610
ENTRY DATE: Entered STN: 19900313
Last Updated on STN: 19900313
Entered Medline: 19761029

L7 ANSWER 8 OF 32 MEDLINE on STN
TI Letter: The effect of contraceptive steroids on carbohydrate metabolism.
AB Comments are made on a short review on the effect of contraceptive s teroids on carbohydrate metabolism which appeared previously. Intraveno us tolbutamide tolerance tests were performed on 13 normal women and 8 hypopituitary patients before and 3 and 6 months after starting on an oral contraceptive agent (OCA) containing 50 mcg mestranol and 1 mg norethindrone. The control subjects demonstrated a significant impairment of the glucose fall after tolbutamide and an enhancement of the growth hormone (GH) response to the resultant **hypoglycemia** while on the OCA. The pituitary-deficient patients showed no change in their glucose response to tolbutamide after starting OCA and they had minimal GH secretion as expected. 5 additional normal females on a variety of OCAs had a significant 3-fold increase in GH concentrations after moderate exercise as compared with 5 other women using other forms of contraception. The peripheral tissues of women on OCAs were exposed to higher levels of GH throughout the day. The data seemed to implicate the anterior pituitary gland, and it was postulated that the estrogen-induced secretion of GH, a potent **insulin antagonist**, was responsible for the effects of OCAs on carbohydrate metabolism. It is concluded through laboratory investigations that there is good evidence to support the role of estrogens alone in causing deterioration of glucose tolerance. This contradicts the review in which it was concluded that carbohydrate metabolism in younger women was unaffected by estrogens alone but will deteriorate in response to a combination of estrogen and nortestosterone progestins.

ACCESSION NUMBER: 74258967 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4834911
TITLE: Letter: The effect of contraceptive steroids on carbohydrate metabolism.
AUTHOR: Davidson M B
SOURCE: Metabolism: clinical and experimental, (1974 Jul) 23 (7) 687-90.
Journal code: 0375267. ISSN: 0026-0495.
Report No.: PIP-741979; POP-00022298.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Population
ENTRY MONTH: 197408

ENTRY DATE: Entered STN: 19900310
Last Updated on STN: 20021101
Entered Medline: 19740828

L7 ANSWER 9 OF 32 MEDLINE on STN
TI Role of synalbumin **insulin antagonist** in pathogenesis of diabetes mellitus.
ACCESSION NUMBER: 70294301 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4918251
TITLE: Role of synalbumin **insulin antagonist** in pathogenesis of diabetes mellitus.
AUTHOR: Davidson M B; Poffenbarger P L
SOURCE: Metabolism: clinical and experimental, (1970 Sep) 19 (9) 668-86. Ref: 115
Journal code: 0375267. ISSN: 0026-0495.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197011
ENTRY DATE: Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19701106

L7 ANSWER 10 OF 32 USPATFULL on STN
TI Insulin-associated peptides with effects on cerebral health
AB The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:19356 USPATFULL
TITLE: Insulin-associated peptides with effects on cerebral health
INVENTOR(S): During, Matthew J., Philadelphia, PA, UNITED STATES
Haile, Colin N., Katy, TX, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014660	A1	20040122	
APPLICATION INFO.:	US 2003-430545	A1	20030506	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-378318P	20020506 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 2477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 32 USPATFULL on STN
TI Treatment of acute coronary syndrome with GLP-1
AB The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:2431 USPATFULL		
TITLE:	Treatment of acute coronary syndrome with GLP-1		
INVENTOR(S):	Coolidge, Thomas R., Falls Village, CT, UNITED STATES Ehlers, Mario, Lincoln, NE, UNITED STATES		
PATENT ASSIGNEE(S):	Amylin Pharmaceuticals, Inc., San Diego, CA, UNITED STATES, 68524 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002454	A1	20040101
APPLICATION INFO.:	US 2002-322839	A1	20021218 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-859804, filed on 18 May 2001, PENDING		
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-205239P		20000519 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ARNOLD & PORTER, Attn: IP Docketing Department, Room 1126B, 555 Twelfth Street, NW, Washington, DC, 20004-1206		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1204		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 32 USPATFULL on STN
TI Novel polypeptide of protein p140 and DNAs encoding it
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent.

Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244456 USPATFULL
TITLE: Novel polypeptide of protein p140 and DNAs encoding it
INVENTOR(S): Tajima, Hisao, Osaka, JAPAN
Kitagawa, Koichiro, Osaka, JAPAN
Ohno, Hiroyuki, Osaka, JAPAN
PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170865	A1	20030911
APPLICATION INFO.:	US 2002-187958	A1	20020703 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-558340, filed on 26 Apr 2000, GRANTED, Pat. No. US 6432913 Division of Ser. No. US 1998-192435, filed on 8 Jan 1998, GRANTED, Pat. No. US 6303320 Division of Ser. No. US 1995-571785, filed on 13 Dec 1995, GRANTED, Pat. No. US 5804411 Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, GRANTED, Pat. No. US 5506205

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 32 USPATFULL on STN
TI Blood glucose level control
AB A pancreatic controller, comprising:

at least one electrode adapted for electrifying at least a portion of a pancreas; and

a controller programmed to electrify said electrode so as to positively control at least the effect of at least two members of a group consisting of blood glucose level, blood insulin level and blood level of another pancreatic hormone. In one example, the controller controls insulin, glucagon and/or glucose blood levels.

ACCESSION NUMBER: 2003:79535 USPATFULL
TITLE: Blood glucose level control
INVENTOR(S): Darvish, Nissim, Hof-Hacarmel, ISRAEL
Harel, Tami, Haifa, ISRAEL
Felsen, Bella, Haifa, ISRAEL
Glasberg, Offer, Haifa, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055464	A1	20030320
APPLICATION INFO.:	US 2002-237263	A1	20020905 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2000-IL566, filed on 13 Sep 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-IL132	20000305

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: William H. Dippert, Esq., Reed Smith LLP, 29th Floor, 599 Lexington Avenue, New York, NY, 10022-7650
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 2529

L7 ANSWER 14 OF 32 USPATFULL on STN
TI Polypeptide of protein p140 and DNAs encoding it
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent.

Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:202054 USPATFULL
TITLE: Polypeptide of protein p140 and DNAs encoding it
INVENTOR(S): Tajima, Hisao, Osaka, JAPAN
Kitagawa, Koichiro, Osaka, JAPAN
Ohno, Hiroyuki, Osaka, JAPAN
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6432913	B1	20020813
APPLICATION INFO.:	US 2000-558340		20000426 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-192435, filed on 8 Jan 1998, now patented, Pat. No. US 6303320 Division of Ser. No. US 1995-571785, filed on 13 Dec 1995, now patented, Pat. No. US 5804411 Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, now patented, Pat. No. US 5506205

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Mitra, Rita
LEGAL REPRESENTATIVE: Sughrue Mion, PLLC
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 32 USPATFULL on STN
TI Treatment of acute coronary syndrome with GLP-1
AB The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:199097 USPATFULL			
TITLE:	Treatment of acute coronary syndrome with GLP-1			
INVENTOR(S):	Coolidge, Thomas R., Falls Village, CT, UNITED STATES Ehlers, Mario, Lincoln, NE, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002107206	A1	20020808	
	US 6706689	B2	20040316	
APPLICATION INFO.:	US 2001-859804	A1	20010518	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-205239P		20000519	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W. Suite 500, Washington, DC, 20007-5109			
NUMBER OF CLAIMS:	47			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1101			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 32 USPATFULL on STN
TI Polypeptide of protein P140 and DNAs encoding it
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the polypeptide; vector derived with the DNA; host cells transformed with the vector; antibody of the polypeptide; pharmaceutical composition containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and the screening methods of the prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:178824 USPATFULL
TITLE:	Polypeptide of protein P140 and DNAs encoding it
INVENTOR(S):	Tajima, Hisao, Osaka, Japan Kitagawa, Koichiro, Osaka, Japan Ohno, Hiroyuki, Osaka, Japan

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303320	B1	20011016
APPLICATION INFO.:	US 1998-192435		19980108 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-571785, filed on 13 Dec 1995, now patented, Pat. No. US 5804411 Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, now patented, Pat. No. US 5506205

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Mitra, Rita
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1169
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 32 USPATFULL on STN
TI Nucleic acid encoding a transcription factor, IDX-1
AB The invention features a novel recombinant polypeptide that transactivates the somatostatin promoter, the polypeptide being present in pancreatic duct cells and not present in pancreatic α-cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:47834 USPATFULL
TITLE: Nucleic acid encoding a transcription factor, IDX-1
INVENTOR(S): Habener, Joel F., Newton Highlands, MA, United States
Miller, Christopher P., Arlington, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6210960	B1	20010403
APPLICATION INFO.:	US 1996-751344		19961119 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-202044, filed on 23 Feb 1994, now patented, Pat. No. US 5858973
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: Palmer & Dodge, LLP, Williams, Kathleen
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1642
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 32 USPATFULL on STN
TI Use of human transferrin in controlling insulin levels
AB The present invention relates to the use of transferrin in controlling insulin levels. Transferrin can disrupt insulin:receptor interactions in mammalian cells, may be used in mammals to treat **hypoglycemia**, may also be used to inhibit production of insulin by mammalian cells,

and can decrease the serum insulin levels in a mammal. The invention further provides methods for identifying compounds which modulate the effect of transferrin on insulin signal transduction. Pharmaceutical compositions containing transferrin are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:67782 USPATFULL
TITLE:	Use of human transferrin in controlling insulin levels
INVENTOR(S):	Vargas, Luis A., Santiago, Chile Faerman, Carlos H., Ithaca, NY, United States Karplus, P. Andrew, Ithaca, NY, United States
PATENT ASSIGNEE(S):	Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6069193		20000530
APPLICATION INFO.:	US 1998-167853		19981007 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-585355, filed on 11 Jan 1996, now patented, Pat. No. US 5849293, issued on 15 Dec 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
ASSISTANT EXAMINER:	Basi, Nirmal S.		
LEGAL REPRESENTATIVE:	Nixon Peabody LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	902		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 32 USPATFULL on STN

TI Transcription factor and uses therefor

AB The invention features a novel recombinant polypeptide that transactivates the somatostatin promoter, the polypeptide being present in pancreatic duct cells and not present in pancreatic α-cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:4631 USPATFULL
TITLE:	Transcription factor and uses therefor
INVENTOR(S):	Habener, Joel F., Newton Highlands, MA, United States Miller, Christopher P., Arlington, MA, United States
PATENT ASSIGNEE(S):	The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5858973		19990112
APPLICATION INFO.:	US 1994-202044		19940223 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Banner & Allegretti, Ltd.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1886		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 32 USPATFULL on STN

TI Use of human transferrin in controlling insulin levels
AB The present invention relates to the use of transferrin in controlling insulin levels. Transferrin can disrupt insulin:receptor interactions in mammalian cells, may be used in mammals to treat **hypoglycemia**, may also be used to inhibit production of insulin by mammalian cells, and can decrease the serum insulin levels in a mammal. The invention further provides methods for identifying compounds which modulate the effect of transferrin on insulin signal transduction. Pharmaceutical compositions containing transferrin are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:156916 USPATFULL		
TITLE:	Use of human transferrin in controlling insulin levels		
INVENTOR(S):	Vargas, Luis A., Santiago, Chile Faerman, Carlos H., Ithaca, NY, United States Karplus, P. Andrew, Ithaca, NY, United States		
PATENT ASSIGNEE(S):	Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849293		19981215
APPLICATION INFO.:	US 1996-585355		19960111 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Walsh, Stephen		
ASSISTANT EXAMINER:	Basi, Nirmal S.		
LEGAL REPRESENTATIVE:	Nixon, Hargrave, Devans & Doyle LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	893		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 32 USPATFULL on STN
TI Polypeptide of protein P140 and DNAS encoding it
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment of diabetes, agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only to improve the diabetes-derived hypoglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:108245 USPATFULL
TITLE:	Polypeptide of protein P140 and DNAS encoding it
INVENTOR(S):	Tajima, Hisao, Osaka, Japan Kitagawa, Koichiro, Osaka, Japan Ohno, Hiroyuki, Osaka, Japan
PATENT ASSIGNEE(S):	Ono Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804411		19980908
APPLICATION INFO.:	US 1995-571785		19951213 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, now patented, Pat. No. US 5506205		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 32 USPATFULL on STN
TI Polypeptide of protein p140 and DNAs encoding it
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector comprising the DNA; host cells transformed with the vector; antibody against the polypeptide; pharmaceutical compositions containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and screening methods for the prevention and/or treatment agent.

Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only to improves the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 96:29534 USPATFULL
TITLE: Polypeptide of protein p140 and DNAs encoding it
INVENTOR(S): Tajima, Hisao, Osaka, Japan
Kitagawa, Koichiro, Osaka, Japan
Ohno, Hiroyuki, Osaka, Japan
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5506205		19960409
APPLICATION INFO.:	US 1994-348143		19941123 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 32 USPATFULL on STN
TI Method of controlling diabetes mellitus
AB The use of precise dosages of insulin-plus-sugar in a method of controlling and/or treating diabetes is disclosed, including the steps of frequently testing both the blood sugar level and the urine sugar level of the diabetic patient; and administering insulin and/or sugar as required by the results of the blood and urine sugar tests. The amount of insulin and/or sugar administered is reviewed daily and modifications are made on a daily basis such that the patient over time will need little or no insulin. The present invention is also related to a method for controlling the out-of-control diabetic patient and to a method for reversing the negative effects already caused by diabetes. This method also avoids the side effects of insulin use such as **hypoglycemia** and hyperinsulinemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 95:47704 USPATFULL
TITLE: Method of controlling diabetes mellitus
INVENTOR(S): Shohet, Isaac H., 70-34 Kissena Blvd., Flushing, NY, United States 11367

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5420108		19950530	
APPLICATION INFO.:	US 1992-943176		19920914	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Jill
ASSISTANT EXAMINER: Davenport, A. M.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 2806
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 32 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -
AN AAB07358 peptide DGENE
AB Type II diabetes mellitus (non-insulin-dependent diabetes mellitus) is caused by defective signal transduction by the insulin receptor, leading to insulin resistance and ultimately an increase in blood glucose levels. The present sequence is the amino-terminal sequence of human alpha2-glycoprotein (alpha2-GP, alpha2-inhibitor). Alpha2-GP is an **insulin antagonist**. The present sequence was used in sequence analysis and showed that alpha2-GP is in fact identical to human serum transferrin (hsTf). Transferrin is a glycoprotein which is needed for the transportation of iron in blood. Transferrin may be administered to type II diabetes mellitus patients due to its insulin antagonism effects.
ACCESSION NUMBER: AAB07358 peptide DGENE
TITLE: Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -
INVENTOR: Karplus P A; Vargas L A; Faerman C H

PATENT ASSIGNEE: (CORR)CORNELL RES FOUND INC.
PATENT INFO: US 6069193 A 20000530 16p
APPLICATION INFO: US 1998-167853 19981007
PRIORITY INFO: US 1996-585355 19960111
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-430142 [37]
DESCRIPTION: Human alpha2-GP amino-terminal sequence # 2.

L7 ANSWER 25 OF 32 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -
AN AAB07357 peptide DGENE
AB Type II diabetes mellitus (non-insulin-dependent diabetes mellitus) is caused by defective signal transduction by the insulin receptor, leading to insulin resistance and ultimately an increase in blood glucose levels. The present sequence is the amino-terminal sequence of human alpha2-glycoprotein (alpha2-GP, alpha2-inhibitor). Alpha2-GP is an **insulin antagonist**. The present sequence was used in sequence analysis and showed that alpha2-GP is in fact identical to human serum transferrin (hsTf). Transferrin is a glycoprotein which is needed for the transportation of iron in blood. Transferrin may be administered to type II diabetes mellitus patients due to its insulin antagonism effects.
ACCESSION NUMBER: AAB07357 peptide DGENE
TITLE: Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -
INVENTOR: Karplus P A; Vargas L A; Faerman C H
PATENT ASSIGNEE: (CORR)CORNELL RES FOUND INC.
PATENT INFO: US 6069193 A 20000530 16p
APPLICATION INFO: US 1998-167853 19981007
PRIORITY INFO: US 1996-585355 19960111
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-430142 [37]
DESCRIPTION: Human alpha2-GP amino-terminal sequence # 1.

L7 ANSWER 26 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and α-cell hyperplasia in prohormone convertase 2 knockout mice.
AB Prohormone convertase 2 (PC2) plays an essential role in the processing of proglucagon to mature active glucagon in pancreatic α-cells (J Biol Chem 276:27197-27202, 2001). Mice lacking PC2 demonstrate multiple defects, including chronic mild **hypoglycemia** and dramatic hyperplasia of the pancreatic α-cells. To define the contribution of mature glucagon deficiency to the **hypoglycemia** and α-cell hyperplasia, we have attempted to correct the defects by delivery of exogenous glucagon by micro-osmotic pumps. Intraperitoneal delivery of 0.5 μg glucagon/h in PC2(-/-) mice resulted in the normalization of blood glucose concentrations. Islet remodeling through the loss of hyperplastic α-cells was evident by day 11 after pump implantation; by 25 days postimplantation, PC2(-/-) islets were indistinguishable from wildtype islets. These rapid changes were brought about by induction of apoptosis in the α-cell population. Morphological normalization of islets was also accompanied by marked downregulation of endogenous preproglucagon gene expression, but with little or no change in the level of preproinsulin gene expression. Exogenous glucagon delivery also normalized hepatic expression of the gluconeogenic enzyme PEPCK. These results demonstrate that the lack of mature glucagon in PC2(-/-) mice is responsible for the aberrant blood glucose levels, islet morphology, and gene expression, and they confirm the role of glucagon as a tonic

insulin antagonist in regulating glycemia.

ACCESSION NUMBER: 2002255057 EMBASE
TITLE: Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and α-cell hyperplasia in prohormone convertase 2 knockout mice.
AUTHOR: Webb G.C.; Akbar M.S.; Zhao C.; Swift H.H.; Steiner D.F.
CORPORATE SOURCE: D.F. Steiner, MC1028, 5841 S. Maryland Ave., Chicago, IL 60637, United States. dfsteine@midway.uchicago.edu
SOURCE: Diabetes, (2002) 51/2 (398-405).
Refs: 37
ISSN: 0012-1797 CODEN: DIAEAZ
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 003 Endocrinology
029 Clinical Biochemistry
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L7 ANSWER 27 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Insulin antagonism: A novel role for human serum transferrin.
AB We have purified α2-glycoprotein (α2-GP), an **insulin antagonist** from human plasma which is induced by growth hormone (GH), and shown that pure (α2-GP is a potent antagonist of severe insulin-induced **hypoglycemia**, producing acute hyperglycemia in intact rats and in diabetic rats. The N- terminal amino acid sequence of α2-GP and the reactivity of α2-GP with an antitransferrin monoclonal antibody show that α2-GP is identical to human serum transferrin. Furthermore, pure human serum transferrin and non-glycosylated recombinant human transferrin reproduce the **insulin antagonist** effects of α2-GP in rats, whereas ovotransferrin shows no such effect. The neutralization of the insulin antagonism of human serum transferrin by an anti-transferrin monoclonal antibody shows that transferrin has a new function as a potent **insulin antagonist**. This novel role for human serum transferrin in the regulation of glucose metabolism provides a reasonable mechanism for the diabetogenic effect of GH, and has important implications for the etiology and progression of diabetes.
ACCESSION NUMBER: 1998125211 EMBASE
TITLE: Insulin antagonism: A novel role for human serum transferrin.
AUTHOR: Vargas L.; Kawada M.E.; Bazaes S.; Karplus P.A.; Faerman C.H.
CORPORATE SOURCE: L. Vargas, Dept. of Cell and Molecular Biology, Pontifical Catholic Univ. of Chile, Casilla 114-D, Santiago, Chile
SOURCE: Hormone and Metabolic Research, (1998) 30/3 (113-117).
Refs: 34
ISSN: 0018-5043 CODEN: HMMRA2
COUNTRY: Germany
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 003 Endocrinology
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L7 ANSWER 28 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI The **insulin-antagonist** effect of the counterregulatory hormones.
AB The counterregulatory hormones glucagon, adrenaline, cortisol and growth hormone are released during hypoglycaemia, and under other stress conditions. These hormones have insulin-antagonistic effects both in the

liver and in the peripheral tissues. The insulin-antagonistic effects of glucagon and adrenaline are of rapid onset, whereas those of cortisol and growth hormone are only observed after a lag period of several hours. Glucagon is the most important hormone for acute glucose counterregulation. When the release of this hormone is deficient, as in patients with insulin-dependent diabetes, adrenaline becomes the most important hormone for glucose recovery during hypoglycaemia. Cortisol and growth hormone contribute to counterregulation during prolonged hypoglycaemia, but adrenaline is also of utmost importance in this condition. Adrenaline induces the early posthypoglycaemic insulin resistance, whereas cortisol and growth hormone are important for the insulin resistance that is observed later following hypoglycaemia. However, the importance of posthypoglycaemic insulin resistance for induction of posthypoglycaemic hyperglycaemia in clinical situations is limited. The pronounced insulin-antagonistic effect of growth hormone indicates that this hormone, in addition to its effect on the dawn phenomenon, could also play a key role in the regulation of other diurnal rhythms of glucose metabolism.

ACCESSION NUMBER: 91193036 EMBASE
DOCUMENT NUMBER: 1991193036
TITLE: The **insulin-antagonist** effect of the counterregulatory hormones.
AUTHOR: Lager I.
CORPORATE SOURCE: Department of Medicine II, Sahlgrenska Hospital, University of Goteborg,S-413 45 Goteborg, Sweden
SOURCE: Journal of Internal Medicine, Supplement, (1991) 229/735 (41-47).
ISSN: 0955-7873 CODEN: JIMSE3
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L7 ANSWER 29 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.
AB With isoelectric focusing, we examined heterogeneity of autoantibodies to insulin receptors in serums of two patients with insulin-resistant diabetes and one patient with **hypoglycemia**. Immunoglobulins were prepared by ammonium sulfate precipitation and ion-exchange chromatography with DEAE-Sepharose and subjected to isoelectric focusing for separation into 30 fractions. The fractions were tested for their ability to inhibit 125I-labeled insulin binding to human placental membranes, immunoprecipitate solubilized insulin receptor cross-linked with 125I-insulin, and mimic or inhibit the action of insulin in rat adipocytes. The results varied among the three patients. In the first patient, inhibition of 125I-insulin-binding activity (IBA) and insulin-receptor-precipitating activity (IPA) were distributed almost identically, but the distribution of insulinlike bioactivity (ILBA) was somewhat different. In the second patient, some fractions exhibited potent IBA without IPA, and these fractions inhibited the action of insulin in rat adipocytes. In the third patient, all of the isoelectric fractions showed IBA without IPA and were insulin antagonists. These observations indicate that some patients have antibodies with pure **insulin-antagonist** properties and provide further evidence that autoantibodies to insulin receptors are polyclonal and recognize different antigenic sites on insulin-receptor molecules. The findings also suggest that the ability of antibodies to elicit ILBA is linked to the ability to immunoprecipitate 125I-insulin-crosslinked and solubilized receptors,

wheras antibodies that only inhibit insulin binding behave as insulin antagonists.

ACCESSION NUMBER: 89250438 EMBASE
DOCUMENT NUMBER: 1989250438
TITLE: Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.
AUTHOR: Tsushima T.; Omori Y.; Murakami H.; Hirata Y.; Shizume K.
CORPORATE SOURCE: Second Department of Medicine, Tokyo Women's Medical College, Tokyo 162, Japan
SOURCE: Diabetes, (1989) 38/9 (1090-1096).
ISSN: 0012-1797 CODEN: DIAEAZ
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 026 Immunology, Serology and Transplantation
003 Endocrinology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L7 ANSWER 30 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.
AB Continuous, low dose, insulin infusion in conscious dogs produced moderate **hypoglycemia** but only a transient fall in glucose production that rose towards preinfusion levels 20 to 30 min before any detectable increase in plasma counterregulatory hormones. Addition of epinephrine or glucagon to the insulin infusion prevented the fall in glucose production throughout the experiment but only partially diminished the hypoglycemic response. When **hypoglycemia** was prevented by a variable glucose infusion, neither epinephrine nor glucagon was able to counteract the suppressive effect of insulin on glucose output. These findings suggest that a fall in blood glucose per se may reverse insulin-induced inhibition of glucose production independent of a rise in counterregulatory hormones and that the **insulin antagonist** effect of counterregulatory hormones is modulated, at least in part, by blood glucose concentration.

ACCESSION NUMBER: 79203514 EMBASE
DOCUMENT NUMBER: 1979203514
TITLE: Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.
AUTHOR: Sacca L.; Cryer P.E.; Sherwin R.S.
CORPORATE SOURCE: Dept. Int. Med., Yale Univ. Sch. Med., New Haven, Conn. 06510, United States
SOURCE: Diabetes, (1979) 28/6 (533-536).
CODEN: DIAEAZ
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
003 Endocrinology
LANGUAGE: English

L7 ANSWER 31 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Hypoglycaemic effects of salivary duct ligation upon diabetes mellitus in mice.
AB The effect of bilateral ligation of the ducts of the submandibular gland or the parotid gland alone or of both glands upon blood sugar levels were investigated in adult male non diabetic Connought Swiss, non diabetic and streptozotocin induced diabetic C57BL/6J and mutant diabetic C57BL/KsJ db/db mice. The hypoglycaemic effect was only consistent and significant when both the parotid and submandibular ducts were simultaneously ligated bilaterally. This effect was most pronounced in mutant diabetic mice. The

mechanism of this effect is discussed with regard to the possible existence of an **insulin antagonist** produced in the submandibular gland.

ACCESSION NUMBER: 77072057 EMBASE
DOCUMENT NUMBER: 1977072057
TITLE: Hypoglycaemic effects of salivary duct ligation upon diabetes mellitus in mice.
AUTHOR: Hoshino K.; Decker R.F.; Molnar F.; Kim Y.T.
CORPORATE SOURCE: Cell. Biol. Res. Lab., Dept. Anat., Fac. Med. Dent., Univ. Manitoba, Winnipeg, Canada
SOURCE: Archives of Oral Biology, (1976) 21/2 (105-111).
CODEN: AOBIAR
DOCUMENT TYPE: Journal
FILE SEGMENT: 003 Endocrinology
002 Physiology
LANGUAGE: English

L7 ANSWER 32 OF 32 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin.
AN 2000-430142 [37] WPIDS
AB US 6069193 A UPAB: 20000807
NOVELTY - Treating type II diabetes mellitus comprises administering transferrin to a mammal suffering from type II diabetes mellitus.

ACTIVITY - Antidiabetic. Intact rats were treated with alpha 2-glycoprotein (GP) alone or in association with a high, **hypoglycemia**-inducing dose of insulin. In all cases, 0.4 immunizing units (IU) insulin per 100 g body weight was used to induce **hypoglycemia**. Inhibition of severe insulin-induced **hypoglycemia** by alpha -2-GP occurred in five intact rats (n=5). Consistent with the high dose of insulin used, the insulin control developed severe **hypoglycemia** with one of the rats dying at 120 min with no detectable blood glucose. alpha 2-GP alone led to a rapid and broad **hypoglycemia**, and when given 10 min before insulin, it showed remarkable ability to antagonize the insulin-induced **hypoglycemia**.

MECHANISM OF ACTION - **Insulin antagonist**. The 80 %-pancreatectomized (80 %-P) rat model was used to assess the effect of alpha 2-GP on insulin levels showed that alpha 2-GP caused a rapid and profound hypoinsulinemia. Insulin levels were monitored in 80 %-P rats after treatment with 50 micro g alpha 2-GP or after 60 min of restrained stress. The resting insulin levels ranged from 8.5-11 micro U/ml, so that the maximal delta -insulinemia of -8.0 seen was dramatic. Results showed that alpha 2-GP did not only antagonize the effects of circulating insulin but also blocked the release of new insulin.

USE - Transferrin is useful for treating type II diabetes mellitus, for decreasing insulin production or serum concentration of insulin in mammals and mammalian cells, and for treating a mammal suffering from or susceptible to **hypoglycemia**.

ADVANTAGE - The new method effectively antagonizes insulin, and increases glycemic control to lessen adverse effects of diabetes.

Dwg.0/7

ACCESSION NUMBER: 2000-430142 [37] WPIDS
DOC. NO. NON-CPI: N2000-320910
DOC. NO. CPI: C2000-130642
TITLE: Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin.
DERWENT CLASS: B04 S03
INVENTOR(S): FAERMAN, C H; KARPLUS, P A; VARGAS, L A
PATENT ASSIGNEE(S): (CORR) CORNELL RES FOUND INC
COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 6069193	A	20000530	(200037)*		16

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 6069193	A Div ex	US 1996-585355	19960111
		US 1998-167853	19981007

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 6069193	A Div ex	US 5849293

PRIORITY APPLN. INFO: US 1996-585355 19960111; US 1998-167853 19981007

=> d his

(FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 17:33:04 ON 09 SEP 2004

```
L1         47616 S HYPERGYLCEMIA OR HYPOGLYCEMIA
L2            17 S L1 AND NON-PEPTIDYL COMPOUND
L3         13598 S L1 AND TREATMENT
L4            10 S L3 AND INSULIN AGONIST
L5           135 S INSULIN ANTAGONIST
L6             1 S L5 AND L4
L7            32 S L5 AND L1

=> s l1 and insulin receptor
L8           665 L1 AND INSULIN RECEPTOR

=> s l8 and binding
L9           470 L8 AND BINDING

=> s l9 and l2
L10           14 L9 AND L2

=> d l10 ti abs ibib tot

L10  ANSWER 1 OF 14  USPATFULL on STN
TI     Insulin-like growth factor agonist molecules
AB     Compounds are provided that inhibit the interaction of an IGF with any
       one of its binding proteins and not to a human IGF receptor.
       These IGF agonist compounds, which include peptides, are useful to
       increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2004:85155  USPATFULL
TITLE:                   Insulin-like growth factor agonist molecules
INVENTOR(S):             Clark, Ross G., Auckland, NEW ZEALAND
                         Lowman, Henry B., El Granada, CA, United States
                         Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):      Genentech, Inc., South San Francisco, CA, United States
                         (U.S. corporation)
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6716586	B1	20040406
APPLICATION INFO.:	US 2000-724065		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:78964 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6713451	B1	20040330
APPLICATION INFO.:	US 2000-724062		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:41453 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND

Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693079	B1	20040217
APPLICATION INFO.:	US 2000-724157		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:41452 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693078	B1	20040217
APPLICATION INFO.:	US 2000-724095		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 65 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:34008 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689751	B1	20040210
APPLICATION INFO.:	US 2000-723912		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:21596 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Devonport, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683053	B1	20040127
APPLICATION INFO.:	US 2000-723913		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Dreger, Esq., Ginger R., Heller Ehrman White & McAuliffe LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5367
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:15030 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, NEW ZEALAND Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6680298	B1	20040120
APPLICATION INFO.:	US 2000-724114		20001128 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David S.
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	44 Drawing Figure(s); 49 Drawing Page(s)
LINE COUNT:	5376

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:9592 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, NEW ZEALAND Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677305	B1	20040113
APPLICATION INFO.:	US 2000-723873		20001128 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David S.
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT:	5359

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:296863 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, NEW ZEALAND Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 6645775	B1 20031111
APPLICATION INFO.:	US 2000-723931	20001128 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David S.
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	67 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT:	5386

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:279179 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, NEW ZEALAND Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 6635619	B1 20031021
APPLICATION INFO.:	US 2000-724127	20001128 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David S.

LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller, Ehrman, White & McAuliffe, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 49 Drawing Page(s)
LINE COUNT: 5375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:273418 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6632794	B1	20031014
APPLICATION INFO.:	US 2000-723547		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:246897 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C.A.F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620789	B1	20030916
APPLICATION INFO.:	US 2000-723901		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar

1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:222090 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6608031	B1	20030819
APPLICATION INFO.:	US 2000-723890		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 5363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 14 USPATFULL on STN
TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:97888 USPATFULL
TITLE: Insulin-like growth factor agonist molecules
INVENTOR(S): Clark, Ross G., Auckland, New Zealand
Lowman, Henry B., El Granada, CA, United States
Robinson, Iain C. A. F., St. Albans, United Kingdom
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 4925
CAS INDEXING IS AVAILABLE FOR THIS PATENT.